Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition ...

The results are undoubtedly exciting, but several points must also be considered. Secondly, serious adverse events occurred in 21 (53%) of 40 patients in the tiragolumab plus atezolizumab plus ...

To date, a total of five FDA-approved drugs are available for patients with advanced cancer following platinum-based chemotherapy: the PD-1 inhibitors pembrolizumab, nivolumab, and atezolizumab, and ...

Unpaired Student's t-test and One-way analysis of variance were used for analyzing statistical significance. A P-value <0.05 was considered significant. Table 2. The IC50 values for 48 h treatment of ...